Advertisement
Singapore markets closed

  • Straits Times Index

    3,316.56
    -6.06 (-0.18%)
     

  • Nikkei

    38,646.11
    -457.11 (-1.17%)
     

  • Hang Seng

    18,608.94
    -259.77 (-1.38%)
     

  • FTSE 100

    8,317.59
    -21.64 (-0.26%)
     

  • Bitcoin USD

    69,085.98
    +839.88 (+1.23%)
     

  • CMC Crypto 200

    1,449.28
    -18.82 (-1.28%)
     

  • S&P 500

    5,304.72
    +36.88 (+0.70%)
     

  • Dow

    39,069.59
    +4.33 (+0.01%)
     

  • Nasdaq

    16,920.79
    +184.76 (+1.10%)
     

  • Gold

    2,335.20
    -2.00 (-0.09%)
     

  • Crude Oil

    77.80
    +0.93 (+1.21%)
     

  • 10-Yr Bond

    4.4670
    -0.0080 (-0.18%)
     

  • FTSE Bursa Malaysia

    1,619.40
    -9.78 (-0.60%)
     

  • Jakarta Composite Index

    7,222.38
    +36.34 (+0.51%)
     

  • PSE Index

    6,619.89
    -40.10 (-0.60%)
     

China approves Shanghai Fosun's unit to run human testing for BioNTech's COVID-19 vaccine

Reuters
·1-min read
Booth of Fosun Pharma is seen at a medical instruments and equipment expo in Beijing

HONG KONG/BEIJING (Reuters) - Shanghai Fosun Pharmaceutical Group said on Friday that its unit has received clinical trial approval from China's National Medical Products Administration for a COVID-19 vaccine candidate developed by German firm BioNTech.

The experimental COVID-19 vaccine, BNT162b2, is more than 90% effective based on initial results from large trials outside China, BioNTech's partner Pfizer Inc said on Monday.

Shanghai Fosun said in a company filing that its unit will begin a Phase II clinical trial in China for the candidate when the conditions are ready.

(Reporting by Twinnie Siu and Roxanne Liu. Editing by Jane Merriman)